Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β 2 -agonists in South Korea
Current medical research and opinion, 2019, Pages 1-1.
The addition of reslizumab to high-dose ICS/LABA was cost-effective in Korean patients with severe eosinophilic asthma uncontrolled with high-dose ICS/LABA, based on the threshold of 1 gross domestic product in Korea.
Full Text (Upload PDF)
PPT (Upload PPT)